MétaCan
Menu
← Back to cohort

Can Pyrimethamine Lower CSF SOD1 Levels in Familial ALS? Results from a Multicenter Phase Ib Trial (S43.007)

2016· article· en· W2547560195 on OpenAlexaboutno aff
Dale J. Lange, Rahul Remanan, Mona Shahbazi, Vincenzo Silani, Albert C. Ludolph, Senda Ajroud‐Driss, Stanley H. Appel, Lindsay Kaplan, Kara G. Fields, Stefan L. Marklund, Peter M. Andersen

Bibliographic record

VenueNeurology · 2016
Typearticle
Languageen
FieldMedicine
TopicAmyotrophic Lateral Sclerosis Research
Canadian institutionsnot available
Fundersnot available
KeywordsPyrimethamineSOD1MedicinePhase (matter)Internal medicinePediatricsImmunologyChemistry

Abstract

fetched live from OpenAlex

Objective: To determine if pyrimethamine can lower CSF SOD1 levels in familial ALS. Background: Reduction of superoxide dismutase 1 (Cu/Zn-SOD1) levels prolongs survival in SOD1 transgenic mouse models of FALS. Pyrimethamine causes a dose dependent reduction of Cu/Zn-SOD1 levels in cell culture systems. Previously, we showed pyrimethamine lowers SOD1 levels in lymphocytes in patients with Cu/Zn-SOD1 mutations. This study investigated whether pyrimethamine lowers cerebrospinal fluid (CSF) Cu/Zn-SOD1 levels in patients with ALS associated with SOD1 mutations. Methods: The study was a multicenter (5 sites), open-label, 9 months duration, dose-ranging clinical study to determine the ability of pyrimethamine to reduce Cu/Zn-SOD1 levels in the CSF of patients with documented Cu/Zn-SOD1 mutation. All participants were to have 3 separate lumbar punctures, blood draws, clinical assessment of strength, motor function, quality of life, and adverse effects assessments. Both Cu/Zn-SOD1 and pyrimethamine levels were measured in the CSF. Blood was analyzed for pyrimethamine levels and Cu/Zn-SOD1 levels in red blood cells. Appel ALS, ALSFRS-R and single item McGill Quality of Life (SiS-MQoL) measures were performed at screening, visit 6 (18 weeks) and 9 (36 weeks). Results: Following approval from Institutional review boards (IRB) at all participating sites, 32 patients (with 23 unique SOD1 mutations) were enrolled in the study; 23 remained in the study for 9 months; 9 did not. A generalized estimating equations (GEE) model was used to analyze CSF SOD1 levels. This model showed a significant reduction in Cu/Zn-SOD1 levels at visit 6 (p<0.001) with a mean CSF Cu/Zn-SOD1 level reduction of 13.5[percnt] (95[percnt] CI(-18.5, -8.4)) and at visit 9 (p<0.001) with a mean reduction of -10.5[percnt] (95[percnt] CI(-15.8, -5.2)). Conclusions: Pyrimethamine is a small molecule that is safe and well tolerated in ALS. This molecule is capable of producing a significant reduction in Cu/Zn-SOD1 levels in FALS patients with Cu/Zn-SOD1 mutations.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.067
GPT teacher head0.353
Teacher spread0.285 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueNeurology→Same topicAmyotrophic Lateral Sclerosis Research→French-language works237,207→